The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Structure-based design of targeted covalent inhibitors
Abstract
Covalent inhibition is a rapidly growing discipline within drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with noncovalent inhibitors, covalent PPI inhibitors can have the advantages of sustained inhibition and longer residence times, as covalently bound PPI targets are persistently inhibited until protein degradation and regeneration [40].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [40]
In the citing paper
“Covalent ligand screening is another ligand discovery approach that is becoming more common, whereby various methods are used to discover covalent ligands from libraries of electrophilic compounds7,12,13.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
In the citing paper
“include the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (AbbVie) and the epidermal growth factor receptor (EGFR) inhibitor osimertinib (AstraZeneca), with sales totalling US$8.43 billion and $4.33 billion in 2020, respectively7,8.”
From Advances in covalent drug discovery (2022) · cites this paper as [7]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Self-citationComputational Methods in Drug Discovery
Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007336 · Cited by 2,160
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Research works printed but not linked: 1
- Martin-Gago, 2017, Cell Chem. Biol., 24, e585
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Put a ring on it: application of small aliphatic rings in medicinal chemistry
Bauer, M. R., Di Fruscia, P., Lucas, S. C. C., Michaelides, I. N., Nelson, J. E., Storer, R. I., & Whitehurst, B. C. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00370k · Cited by 479
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Liu, X. R., Zhang, M. M., & Gross, M. L. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00815 · Cited by 242
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 216
Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics
Li, Q., Chen, Q., Klauser, P. C., Li, M., Zheng, F., Wang, N., Li, X., Zhang, Q., Fu, X., Wang, Q., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.028 · Cited by 210
The Ascension of Targeted Covalent Inhibitors
Singh, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02134 · Cited by 193
Su, H., Yao, S., Zhao, W., Zhang, Y., Liu, J., Shao, Q., Wang, Q., Li, M., Xie, H., Shang, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23751-3 · Cited by 188
Beck, H., Härter, M., Haß, B., Schmeck, C., & Baerfacker, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.015 · Cited by 198
Light-driven post-translational installation of reactive protein side chains
Josephson, B., Fehl, C., Isenegger, P. G., Nadal, S., Wright, T. H., Poh, A. W. J., Bower, B. J., Giltrap, A. M., Chen, L., Batchelor-McAuley, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2733-7 · Cited by 180
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation
Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S., & Kostic, M. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.09.012 · Cited by 178
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 163
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Mirzaei, S., Gholami, M. H., Hushmandi, K., Hashemi, F., Zabolian, A., Canadas, I., Zarrabi, A., Nabavi, N., Aref, A. R., Crea, F., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01235-1 · Cited by 161
Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors
Lu, X., Smaill, J. B., Patterson, A. V., & Ding, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01719 · Cited by 150
Gambini, L., Baggio, C., Udompholkul, P., Jossart, J. N., Salem, A. F., Perry, J. J. P., & Pellecchia, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00561 · Cited by 148
Xiong, M., Su, H., Zhao, W., Xie, H., Shao, Q., & Xu, Y. (2021) · Medicinal Research Reviews · doi:10.1002/med.21783 · Cited by 139
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
Kalyukina, M., Yosaatmadja, Y., Middleditch, M., Patterson, A. V., Smaill, J. B., & Squire, C. J. (2019) · ChemMedChem · doi:10.1002/cmdc.201800719 · Cited by 130
Characterising covalent warhead reactivity
Martin, J. S., Mackenzie, C. J., Fletcher, D., & Gilbert, I. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.002 · Cited by 139
“A “reversible” covalent inhibitor would be for example the trifluoroketone (1), the oxaborole (3) and the nitriles (5, 7, 8, 9), where a reversible reaction could potentially regenerate the inhibitor.”
BackgroundWatterson, S. H., Liu, Q., Bertrand, M. B., Batt, D. G., Li, L., Pattoli, M. A., Skala, S., Cheng, L., Obermeier, M. T., Moore, R., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00167 · Cited by 120
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
Sanders, B., Pokhrel, S., Labbe, A. D., Mathews, I. I., Cooper, C. J., Davidson, R. B., Phillips, G., Weiss, K. L., Zhang, Q., O’Neill, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37254-w · Cited by 129
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Nichols, C. A., Gibson, W. J., Brown, M. S., Kosmicki, J. A., Busanovich, J. P., Wei, H. Y., Urbanski, L. M., Currimjee, N., Berger, A. C., Gao, G. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16399-y · Cited by 122
Covalent fragment libraries in drug discovery
Keeley, A. B., Petri, L., Ábrányi‐Balogh, P., & Keserű, G. M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.016 · Cited by 117
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 122
“[57] and is not exclusively discussed here.”
Wang, Z., Cai, J., Cheng, J., Yang, W., Zhu, Y., Li, H., Lu, T., Chen, Y., & Lü, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01851 · Cited by 105
Covalent Small Molecules as Enabling Platforms for Drug Discovery
Dalton, S. E., & Campos, S. (2019) · ChemBioChem · doi:10.1002/cbic.201900674 · Cited by 104
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“Compared with noncovalent inhibitors, covalent PPI inhibitors can have the advantages of sustained inhibition and longer residence times, as covalently bound PPI targets are persistently inhibited until protein degradation and regeneration [40].”
BackgroundKeeley, A. B., Ábrányi-Balogh, P., & Keserű, G. M. (2018) · MedChemComm · doi:10.1039/c8md00327k · Cited by 97
An update on the discovery and development of reversible covalent inhibitors
Faridoon, F., Ng, R. A., Zhang, G., & Li, J. J. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03065-3 · Cited by 106
“within a target protein family if a poorly conserved cysteine is specifically targeted with a covalent warhead from a drug [2, 4].”
BackgroundHuang, Q., Zhong, Y., Dong, H., Zheng, Q., Shi, S., Zhu, K., Qu, X., Hu, W., Zhang, X., & Wang, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111922 · Cited by 96
Zaidman, D., Gehrtz, P., Filep, M., Fearon, D., Gabizon, R., Douangamath, A., Prilusky, J., Duberstein, S., Cohen, G., Owen, C. D., et al. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.018 · Cited by 88
Mix-and-inject XFEL crystallography reveals gated conformational dynamics during enzyme catalysis
Dasgupta, M., Budday, D., de Oliveira, S. H. P., Madzelan, P., Marchany‐Rivera, D., Seravalli, J., Hayes, B., Sierra, R. G., Boutet, S., Hunter, M. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901864116 · Cited by 87
“Moreover, cysteine residues are attractive targets for covalent inhibitors, which hold great promise for the generation of highly potent and selective drugs (11).”
BackgroundKettle, J. G., Bagal, S. K., Bickerton, S., Bodnarchuk, M. S., Breed, J., Carbajo, R. J., Cassar, D. J., Chakraborty, A., Cosulich, S. C., Cumming, I. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01720 · Cited by 84
Ueda, T., Tamura, T., Kawano, M., Shiono, K., Hóbor, F., Wilson, A. J., & Hamachi, I. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00703 · Cited by 88
McAulay, K., Hoyt, E. A., Thomas, M. C., Schimpl, M., Bodnarchuk, M. S., Lewis, H. J., Barratt, D. G., Bhavsar, D., Robinson, D. M., Deery, M. J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13391 · Cited by 91
Self-citationMorawietz, T., & Artrith, N. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00346-6 · Cited by 93
Nucleophilicity of Glutathione: A Link to Michael Acceptor Reactivities
Mayer, R. J., & Ofial, A. R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909803 · Cited by 86
CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors
Du, H., Gao, J., Weng, G., Ding, J., Chai, X., Pang, J., Kang, Y., Li, D., Cao, D., & Hou, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa876 · Cited by 80
“Second, computer-aided drug design is playing an increasingly important role in the discovery of covalent inhibitors (29).”
BackgroundAljoundi, A., Bjij, I., El-Rashedy, A. A. E., & Soliman, M. E. S. (2020) · The Protein Journal · doi:10.1007/s10930-020-09884-2 · Cited by 84
Visible‐Light‐Induced Cysteine‐Specific Bioconjugation: Biocompatible Thiol–Ene Click Chemistry
Choi, H., Kim, M., Jang, J., & Hong, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202010217 · Cited by 80
Vinylphosphonites for Staudinger-induced chemoselective peptide cyclization and functionalization
Kasper, M., Glanz, M., Oder, A., Schmieder, P., von Kries, J. P., & Hackenberger, C. P. R. (2019) · Chemical Science · doi:10.1039/c9sc01345h · Cited by 76
Wang, Z., Cherukupalli, S., Xie, M., Wang, W., Jiang, X., Jia, R., Pannecouque, C. C., Clercq, E. D., Kang, D., Zhan, P., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01758 · Cited by 78
Birkholz, A. B., Kopecky, D. J., Volak, L. P., Bartberger, M. D., Chen, Y., Tegley, C. M., Arvedson, T., McCarter, J. D., Fotsch, C. H., & Cee, V. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00749 · Cited by 78
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Zhang, D., He, G., & Meng, F. (2021) · Molecules · doi:10.3390/molecules26164907 · Cited by 79
“Therefore, researchers generally agree that reversible inhibitors are more suitable than irreversible ones, both in theory and in practice, for the treatment of these diseases [66,67,81,91,98].”
BackgroundThe expanding repertoire of covalent warheads for drug discovery
Mehta, N. V., & Degani, M. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103799 · Cited by 86
Podoll, T., Pearson, P. G., Evarts, J., Ingallinera, T., Бибикова, Е., Sun, H., Gohdes, M. A., Cardinal, K. A., Sanghvi, M., & Slatter, J. G. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084459 · Cited by 74
“Recent regulatory approvals of TCIs of other protein kinases have led to interest in identifying desirable physicochemical and absorption, distribution, metabolism, and excretion (ADME) properties in drug candidates (Liu et al., 2013; Moghaddam et al., 2014; Baillie, 2016; Lonsdale and Ward, 2018).”
BackgroundDevelopment of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Itaconate is a covalent inhibitor of the Mycobacterium tuberculosis isocitrate lyase
Kwai, B. X. C., Collins, A. J., Middleditch, M., Sperry, J., Bashiri, G., & Leung, I. K. H. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00301h · Cited by 75
Wang, D., Zhang, J., Huang, Z., Yang, Y., Fu, T., Yang, Y. P., Lyu, Y., Jiang, J., Qiu, L., Cao, Z. C., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01263 · Cited by 72
Chemical technology principles for selective bioconjugation of proteins and antibodies
Chauhan, P. S., Ragendu, V., Kumar, M., Molla, R., Mishra, S. D., Basa, S., & Rai, V. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00715d · Cited by 79
Baggio, C., Udompholkul, P., Gambini, L., Salem, A. F., Jossart, J. N., Perry, J. J. P., & Pellecchia, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01108 · Cited by 68
Recent progress in covalent warheads for in vivo targeting of endogenous proteins
Shindo, N., & Ojida, A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116386 · Cited by 71
Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor
Shraga, A., Olshvang, E., Davidzohn, N., Khoshkenar, P., Germain, N., Shurrush, K. A., Carvalho, S., Avram, L., Albeck, S., Unger, T., et al. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.011 · Cited by 69
Fragment-based drug discovery supports drugging ‘undruggable’ protein–protein interactions
Wang, Z.-Z., Shi, X.-X., Huang, G.-Y., Hao, G., & Yang, G. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.01.008 · Cited by 68
Identification of a novel PHGDH covalent inhibitor by chemical proteomics and phenotypic profiling
Chen, C., Zhu, T., Liu, X., Zhu, D., Zhang, Y., Wu, S., Han, C., Zhang, H., Luo, J., & Kong, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.008 · Cited by 67
Furman, R. R., Byrd, J. C., Owen, R. G., O'Brien, S. M., Brown, J. R., Hillmen, P., Stephens, D. M., Chernyukhin, N., Lezhava, T., Hamdy, A., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01252-y · Cited by 64
“named the 3F-cysteine for its location in the ATP pocket, that are targeted by covalent BTK inhibitors [32, 33].”
BackgroundFerlenghi, F., Scalvini, L., Vacondio, F., Castelli, R., Bozza, N., Marseglia, G., Rivara, S., Lodola, A., Monica, S. L., Minari, R., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113786 · Cited by 66
How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor‐Williams, E., & Rowley, C. N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00454 · Cited by 58
Voice, A. T., Tresadern, G., Twidale, R. M., van Vlijmen, H., & Mulholland, A. J. (2021) · Chemical Science · doi:10.1039/d0sc06122k · Cited by 55
Perspectives on Computational Enzyme Modeling: From Mechanisms to Design and Drug Development
Nam, K., Shao, Y., Major, D. T., & Wolf‐Watz, M. (2024) · ACS Omega · doi:10.1021/acsomega.3c09084 · Cited by 85
Approaches to mitigate the risk of serious adverse reactions in covalent drug design
Baillie, T. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1832079 · Cited by 57
CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
Gao, M., Moumbock, A. F. A., Qaseem, A., Xu, Q., & Günther, S. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab868 · Cited by 56
Jiang, L., Liu, S., Jia, X., Gong, Q., Wen, X., Lu, W., Yang, J., Wu, X., Wang, X., Suo, Y., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c08852 · Cited by 55
Biospecific Chemistry for Covalent Linking of Biomacromolecules
Cao, L., & Wang, L. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00066 · Cited by 53
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
“Utilization of a covalent mechanism of inhibition has the potential for increased potency and selectivity, with longer duration of action compared to non-covalent binders [15,16].”
BackgroundHow the Local Environment of Functional Sites Regulates Protein Function
Mazmanian, K., Sargsyan, K., & Lim, C. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c02430 · Cited by 49
Peptide‐based covalent inhibitors of protein–protein interactions
Paulussen, F. M., & Grossmann, T. N. (2022) · Journal of Peptide Science · doi:10.1002/psc.3457 · Cited by 58
Fumarola, C., Bozza, N., Castelli, R., Ferlenghi, F., Marseglia, G., Lodola, A., Bonelli, M. A., Monica, S. L., Cretella, D., Alfieri, R. R., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00179 · Cited by 48
“The clinical experience gained in the field of EGFR and BTK kinases (19) have shown that compounds of this kind are more therapeutically effective than their reversible analogs, in light of the following properties: (i) irreversible inhibitors do not readily dissociate from the engaged target thanks to the formation o…”
BackgroundInfluentialLi, B., Li, Y., Tomkiewicz-Raulet, C., Dao, P., Lietha, D., Yen‐Pon, E., Du, Z., Coumoul, X., Garbay, C., Ethève‐Quelquejeu, M., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01059 · Cited by 51
Gadalla, M. R., & Veit, M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696306 · Cited by 44
“Cysteines are rare in proteins, but are essential for the catalytic activity of ZDHHCs [189].”
BackgroundThe role of quantum chemistry in covalent inhibitor design
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2021) · International Journal of Quantum Chemistry · doi:10.1002/qua.26768 · Cited by 48
Tan, C., Kim, M., Park, I., Kim, Y., & Hong, S. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202213857 · Cited by 48
Pseudomonas fluorescens isocyanide hydratase at 274 K G150A mutant
Wilson, M. A., Dasgupta, M., & Bedem, H. V. D. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6ni5/pdb · Cited by 46
Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00834 · Cited by 47
Chen, C., Gong, L., Liu, X., Zhu, T., Zhou, W.-X., Kong, L., & Luo, J. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102130 · Cited by 43
“Affinity-based protein profiling (ABPP), as a chemical proteomics strategy, is usually employed to identify the protein targets of bioactive small molecules [33,34].”
BackgroundCovalent binders in drug discovery
Vasudevan, A., Argiriadi, M. A., Baranczak, A., Friedman, M., Gavrilyuk, J. I., Hobson, A. D., Hulce, J. J., Osman, S., & Wilson, N. S. (2019) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.12.002 · Cited by 46
Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
Ge, R., Shen, Z., Yin, J., Chen, W., Zhang, Q., An, Y., Tang, D., Satz, A. L., Su, W., & Kuai, L. (2022) · SLAS DISCOVERY · doi:10.1016/j.slasd.2022.01.001 · Cited by 43
Jiang, Y., Rakesh, K. P., Alharbi, N. S., Kameshwar, V. H., Manukumar, H. M. G., Mohammed, Y. H. I., & Qin, H. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103015 · Cited by 44
Advanced approaches of developing targeted covalent drugs
Gai, C., Harnor, S. J., Zhang, S., Cano, C., Zhuang, C., & Zhao, Q. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00216g · Cited by 47
Bianco, G., Goodsell, D. S., & Forli, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.005 · Cited by 44
“The TCI approach has already shown significant successes: kinase TCI have been approved by the FDA for the treatment of cancer, including ibrutinib and acalabrutinib targeting BTK and afatinib and osimertinib against EGFR [2].”
MethodFrom Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Computational chemistry strategies in natural product synthesis
Elkin, M., & Newhouse, T. R. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00351c · Cited by 41
Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics
Yu, H. S., Gao, C., Lupyan, D., Wu, Y., Kimura, T., Wu, C., Jacobson, L., Harder, E., Abel, R., & Wang, L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00268 · Cited by 39
Ma, Y., Li, L., He, S., Shang, C., Sun, Y., Liu, N., Meek, T. D., Wang, Y., & Shang, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00387 · Cited by 39
Stereodefined rhodium-catalysed 1,4-H/D delivery for modular syntheses and deuterium integration
Wang, W., Yu, Y., Cheng, B. H., Fang, H., Zhang, X., Qian, H., & Ma, S. (2021) · Nature Catalysis · doi:10.1038/s41929-021-00643-9 · Cited by 38
Li, S., Zhang, P., Xu, F., Hu, S., Liu, J.-C., Tan, Y., Tu, Z., Sun, H., Zhang, Z., He, Q., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00272 · Cited by 40
Covalent drug discovery using sulfur(VI) fluoride exchange warheads
Huang, H., & Jones, L. H. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2218642 · Cited by 39
“gous amino acid residue selectively targeted by the ligand [3].”
BackgroundCurrent and Future Challenges in Modern Drug Discovery
Tautermann, C. S. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_1 · Cited by 46
Reactive chemistry for covalent probe and therapeutic development
Grams, R. J., & Hsu, K. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.12.002 · Cited by 38
CovBinderInPDB: A Structure-Based Covalent Binder Database
Guo, X.-K., & Zhang, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01216 · Cited by 37
Genetically encoding latent bioreactive amino acids and the development of covalent protein drugs
Wang, N., & Wang, L. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.102106 · Cited by 36
Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides
Charoenpattarapreeda, J., Tan, Y. S., Iegre, J., Walsh, S. J., Fowler, E., Eapen, R. S., Wu, Y., Sore, H. F., Verma, C. S., Itzhaki, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04022f · Cited by 35
Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics
Yoo, D. Y., Hauser, A. D., Joy, S. T., Bar‐Sagi, D., & Arora, P. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00204 · Cited by 37
Meden, A., Knez, D., Brazzolotto, X., Nachon, F., Dias, J., Svete, J., Stojan, J., Grošelj, U., & Gobec, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114248 · Cited by 33
Udompholkul, P., Garza-Granados, A., Alboreggia, G., Baggio, C., McGuire, J. R., Pegan, S. D., & Pellecchia, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00467 · Cited by 40
Huang, Y., Xu, Y., Song, R., Ni, S., Liu, J., Xu, Y., Ren, Y., Rao, L., Wang, Y., Wei, L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00699 · Cited by 33
Zhang, K., Zhang, Y., Li, M., Pannecouque, C. C., Clercq, E. D., Wang, S., & Chen, F. (2024) · Medicinal Research Reviews · doi:10.1002/med.22080 · Cited by 35
Metadata
- Authors
- Lonsdale, R., & Ward, R. A.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Ward, Richard A.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2018
- Volume
- 47
- Issue
- 11
- Pages
- 3816-3830
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2796108867
- Cited by
- 344
- References
- 49
- Citations by year
- 2026: 30 · 2025: 42 · 2024: 46 · 2023: 49 · 2022: 47 · 2021: 45 · 2020: 46 · 2019: 31 · 2018: 8
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- targeted covalent inhibitors, covalent inhibition, structure-based drug design, reactive functional groups, small molecule inhibitors, inhibitor selectivity, covalent drug discovery
- MeSH terms
- Humans, Drug Design, Molecular Structure, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.